Healthcare

CSL Limited (ASX:CSL)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 276-5.7 (2.023%)

(as on 2022-01-16 20:35:53 AEDT)

Market Cap : AUD 132.135 B

Dividend Yield (Annualized) : 1.060%

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
281.7 280 276 275.100L 281.000 H 242.000L 319.780 H
Last Trade 276
Change% -2.0234
52 W H/L 319.780/242.000
EBITDA 3.629 B
NPAT After Abnormal Items 3.159 B
Equity 11.148 B
ROE% 29.46%
Total Liabilities 13.003 B
Total Revenue 13.714 B
Cash and Cash Equivalents 2.406 B

Stock Information

Share price 276
Market Cap 132.135 B
Price/Gross Cash Flow 35.45
Dividend Yield Excluding Special 1.03%
Ending Shares 455.126 M
52-Week Range 319.780-242.000
P/E ratio 38.610
Sector P/E --
EPS 693.00
EV/EBITDA 27.31
Net Profit Margin (%) 24.05%
Gross Cash Flows Per Share 8.03
Net Gearing 47.70%
Gross DPS (AUD) 3.0069
Gross Dividend Yield (Annualized) 1.05%
Earnings Yield 2.590
Net Tangible Asset (NTA) 16.69
Sales Per Share 29.95
Book Value Per Share 24.50

Announcements

Heading Date/Time
Notification of cessation of securities - CSL  12/11/2021 11:29AM
Ceasing to be a substantial holder  11/11/2021 8:29AM
Change of Director's Interest Notice  10/11/2021 11:20AM
Change of Director's Interest Notice  04/11/2021 11:10AM
2021 Annual R&D Day  19/10/2021 8:37AM
Change of Director's Interest Notice  15/10/2021 9:55AM
Notification regarding unquoted securities - CSL  15/10/2021 9:53AM
Results of Meeting  12/10/2021 2:37PM
CSL 2021 Annual General Meeting Speeches  12/10/2021 8:45AM
CSL Notice of Research & Development Investor Briefing  11/10/2021 1:50PM
Notification of cessation of securities - CSL  07/10/2021 10:55AM
Change of Director's Interest Notice  06/10/2021 12:22PM
Change of Director's Interest Notice  05/10/2021 3:24PM
Notification regarding unquoted securities - CSL  05/10/2021 3:22PM
Application for quotation of securities - CSL  04/10/2021 9:34AM
Application for quotation of securities - CSL  17/09/2021 1:07PM
Application for quotation of securities - CSL  14/09/2021 11:57AM
Notification regarding unquoted securities - CSL  09/09/2021 11:06AM
Update - Dividend/Distribution - CSL  07/09/2021 10:35AM
Application for quotation of securities - CSL  07/09/2021 10:02AM
Change of Director's Interest Notice  03/09/2021 2:14PM
Change of Director's Interest Notice  03/09/2021 2:13PM
Notification of cessation of securities - CSL  03/09/2021 1:54PM
Application for quotation of securities - CSL  03/09/2021 1:52PM
Appendix 4G  03/09/2021 8:24AM
CSL Notice of Meeting and Shareholder Pack 2021  03/09/2021 8:24AM
CSL Annual Report  03/09/2021 8:24AM
Change of Director's Interest Notice  27/08/2021 4:05PM
Notification regarding unquoted securities - CSL  27/08/2021 4:02PM

Similar Companies

Related Articles

Load More

About Company

CSL Limited (ASX: CSL) is under the health care segment, and the company is engaged into development, research, manufacturing and marketing of cell culture media, human plasma fractions and pharmaceutical and diagnostic products. It is a biotherapeutics company and its segments include Seqirus, CSL Behring and CSL Intellectual Property. Other than Australia company has facilities in Switzerland, the United Kingdom and the United States. The company was incorporated in 1991 and is based in Poplar Road, Parkville, Australia.

Corporate Information

company address 45 Poplar Road, PARKVILLE, VIC, AUSTRALIA, 3052

company phone(03) 9389 1911

company websitehttp://www.csl.com.au/

Dividends

Year-end Date Franking DPS (AUD) Dividend Yield
30/06/2021 5% 2.939 1.05%
30/06/2020 0% 2.941 1.02%
30/06/2019 0% 1.455 0.68%
30/06/2018 0% 1.005 0.52%
30/06/2017 0% 1.774 1.29%
30/06/2016 0% 1.701 1.52%
30/06/2015 0% 1.607 1.86%
30/06/2014 0% 1.229 1.85%
30/06/2013 0% 1.042 1.69%
30/06/2012 0% 0.830 2.11%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-09-02 2022
Report (Prelim) 2022-08-17 2022
Report (Interim) 2022-02-17 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue 13.274 B 12.817 B 11.7 B 10.266 B 8.601 B
Other Revenue 439.612 M 516.101 M 475.118 M 442.971 M 399.116 M
Total Revenue 13.714 B 13.334 B 12.175 B 10.709 B 9 B
Interest Income 5.188 M 10.2 M 19.678 M 12.583 M 14.171 M
Interest Expenses -227.188 M -219.729 M -251.961 M -146.665 M -117.005 M
Expenses -8.766 B -8.764 B -8.07 B -7.044 B -6.491 B
EBITDA 4.948 B 4.57 B 4.106 B 3.665 B 2.509 B
Depreciation and Amortization -658.819 M -611.686 M -535.292 M -401.434 M -209.828 M
Depreciation -531.258 M -506.047 M -389.42 M -323.231 M -117.005 M
Amortisation -127.561 M -105.639 M -145.872 M -78.203 M -92.824 M
EBIT 4.289 B 3.958 B 3.571 B 3.264 B 2.3 B
Pre Tax Profit 4.067 B 3.749 B 3.338 B 3.13 B 2.197 B
Tax Expense -782.256 M -685.123 M -602.31 M -747.26 M -458.138 M
Net Profit After Tax 3.285 B 3.064 B 2.736 B 2.382 B 1.739 B
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items -125.432 M 0 0 -43.296 M 0
Reported Net Profit After Abnormal Items 3.159 B 3.064 B 2.736 B 2.339 B 1.739 B
Ending Shares 455.126 M 454.049 M 453.139 M 452.401 M 453.252 M
Weighted Average Shares 455.854 M 455.58 M 454.023 M 453.899 M 456.295 M
EPS After Abnormal Items (cents) 693 672.45 602.6 515.36 381.05
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 9.829 B 9.393 B 7.9 B 6.756 B 5.983 B
Total Non Current Assets 14.322 B 13.141 B 9.66 B 7.821 B 5.877 B
Total Assets 24.151 B 22.533 B 17.559 B 14.578 B 11.86 B
Total Current Liabilities 4.128 B 3.12 B 3.12 B 2.591 B 2.104 B
Total Non Current Liabilities 8.875 B 9.902 B 6.951 B 6.467 B 5.643 B
Total Liabilities 13.003 B 13.022 B 10.071 B 9.058 B 7.747 B
Net Assets 11.148 B 9.511 B 7.488 B 5.52 B 4.113 B
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash 4.818 B 3.626 B 2.345 B 2.574 B 1.621 B
Net Invested Cash -2.226 B -1.991 B -1.836 B -2.076 B -1.122 B
Net Financing Cash Flows -1.865 B -936.471 M -700.841 M -502.638 M -134.555 M
Beginning Cash 1.531 B 958.473 M 1.159 B 1.141 B 721.919 M
End Cash Position 2.301 B 1.678 B 937.972 M 1.1 B 1.096 B
Exchange Rate Adjustments 42.431 M 21.273 M -29.231 M -36.26 M 9.75 M
Other Cash Adjustments 0 0 0 0 0
Ending Cash 2.301 B 1.678 B 937.972 M 1.1 B 1.096 B

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK